{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:16:19Z","timestamp":1794266179928,"version":"4.9.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":363,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["Unrestricted educational grant"],"award-info":[{"award-number":["Unrestricted educational grant"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1136\/esmoopen-2020-000858","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T17:40:13Z","timestamp":1602265213000},"page":"e000858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open\u2013Cancer Horizons roundtable discussion"],"prefix":"10.1016","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct03564678","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Patrick W.","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Douer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2020-000858_bb0010","author":"Gupta"},{"key":"10.1136\/esmoopen-2020-000858_bb0015","author":"Sallan"},{"key":"10.1136\/esmoopen-2020-000858_bb0020","author":"Amylon"},{"key":"10.1136\/esmoopen-2020-000858_bb0025","author":"Douer"},{"key":"10.1136\/esmoopen-2020-000858_bb0030","author":"Stock"},{"key":"10.1136\/esmoopen-2020-000858_bb0035","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.80.80","article-title":"A multicenter phase II study using a dose intensified Pegylated-Asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI all Consortium trial","volume":"126","author":"DeAngelo","year":"2015","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0040","author":"Ribera"},{"key":"10.1136\/esmoopen-2020-000858_bb0045","author":"Huguet"},{"key":"10.1136\/esmoopen-2020-000858_bb0050","author":"Douer"},{"key":"10.1136\/esmoopen-2020-000858_bb0055","author":"Toft"},{"key":"10.1136\/esmoopen-2020-000858_bb0060","author":"G\u00f6kbuget"},{"key":"10.1136\/esmoopen-2020-000858_bb0065","author":"Siegel"},{"key":"10.1136\/esmoopen-2020-000858_bb0070","author":"Kozlowski"},{"key":"10.1136\/esmoopen-2020-000858_bb0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3762.3762","article-title":"Poor outcomes with HyPer CVAD induction for T-cell lymphoblastic leukemia\/lymphoma","volume":"126","author":"Kota","year":"2015","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0080","author":"Quist-Paulsen"},{"key":"10.1136\/esmoopen-2020-000858_bb0085","author":"Stock"},{"key":"10.1136\/esmoopen-2020-000858_bb0090","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.494.494","article-title":"PEG-Asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German multicenter study Group for adult all (GMALL) study 07\/2003","volume":"116","author":"Goekbuget","year":"2010","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2017.12.013","article-title":"Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses","volume":"66","author":"Burke","year":"2018","journal-title":"Leuk Res"},{"key":"10.1136\/esmoopen-2020-000858_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2020-000858_bb0105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ejh.12600","article-title":"Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia","volume":"96","author":"Aldoss","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1136\/esmoopen-2020-000858_bb0110","doi-asserted-by":"crossref","first-page":"e26891","DOI":"10.1002\/pbc.26891","article-title":"Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens","volume":"65","author":"Denton","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1136\/esmoopen-2020-000858_bb0115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3903.3903","article-title":"Frontline-Treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance)","volume":"122","author":"Advani","year":"2013","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0120","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0125","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115486","article-title":"Pediatric-Inspired chemotherapy incorporating Pegaspargase is safe and results in high rates of MRD negativity in adults ages 18-60 with Philadelphia chromosome-negative acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"132","author":"Geyer","year":"2018","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0130","author":"Bodmer"},{"key":"10.1136\/esmoopen-2020-000858_bb0135","author":"Rausch"},{"key":"10.1136\/esmoopen-2020-000858_bb0140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1078155217701291","article-title":"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen","volume":"24","author":"Christ","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1136\/esmoopen-2020-000858_bb0145","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12072-019-09971-2","article-title":"Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis","volume":"13","author":"Kamal","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1136\/esmoopen-2020-000858_bb0150","author":"Alshiekh-Nasany"},{"key":"10.1136\/esmoopen-2020-000858_bb0155","author":"Albertsen"},{"key":"10.1136\/esmoopen-2020-000858_bb0160","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","article-title":"Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno toxicity Working Group study","volume":"18","author":"Wolthers","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2020-000858_bb0165","author":"Liu"},{"key":"10.1136\/esmoopen-2020-000858_bb0170","author":"Wolthers"},{"key":"10.1136\/esmoopen-2020-000858_bb0175","author":"Rank"},{"key":"10.1136\/esmoopen-2020-000858_bb0180","author":"Kearney"},{"key":"10.1136\/esmoopen-2020-000858_bb0185","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124727","article-title":"Pegaspargase can safely be administered in adults age 40 and older with acute lymphoblastic leukemia","volume":"134","author":"Daley","year":"2019","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0190","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2020-000858_bb0195","author":"Persson"},{"key":"10.1136\/esmoopen-2020-000858_bb0200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pbc.26183","article-title":"Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia","volume":"64","author":"Raja","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1136\/esmoopen-2020-000858_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28040","article-title":"Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia","volume":"67","author":"Finch","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1136\/esmoopen-2020-000858_bb0210","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12562","article-title":"Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"96","author":"Toft","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1136\/esmoopen-2020-000858_bb0215","author":"Rank"},{"key":"10.1136\/esmoopen-2020-000858_bb0220","author":"Sor\u00e0"},{"key":"10.1136\/esmoopen-2020-000858_bb0225","author":"Athale"},{"key":"10.1136\/esmoopen-2020-000858_bb0230","author":"Tuckuviene"},{"key":"10.1136\/esmoopen-2020-000858_bb0235","article-title":"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen","volume":"1078155217701291","author":"Christ","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1136\/esmoopen-2020-000858_bb0240","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-Term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2020-000858_bb0245","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2141.2007.06677.x","article-title":"Thrombosis and acute lymphoblastic leukaemia","volume":"138","author":"Payne","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1136\/esmoopen-2020-000858_bb0250","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2012.290","article-title":"The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia","volume":"27","author":"Truelove","year":"2013","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2020-000858_bb0255","author":"Leone"},{"key":"10.1136\/esmoopen-2020-000858_bb0260","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V83.2.386.386","article-title":"Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency","volume":"83","author":"Mitchell","year":"1994","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0265","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11239-017-1597-7","article-title":"The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia","volume":"45","author":"Grace","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"10.1136\/esmoopen-2020-000858_bb0270","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/j.1538-7836.2010.04034.x","article-title":"Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors","volume":"8","author":"van Zaane","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1136\/esmoopen-2020-000858_bb0275","author":"Ku"},{"key":"10.1136\/esmoopen-2020-000858_bb0280","author":"Grace"},{"key":"10.1136\/esmoopen-2020-000858_bb0285","author":"Mitchell"},{"key":"10.1136\/esmoopen-2020-000858_bb0290","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.leu.2404560","article-title":"Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study","volume":"21","author":"Farinasso","year":"2007","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2020-000858_bb0295","author":"Ziegler"},{"key":"10.1136\/esmoopen-2020-000858_bb0300","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1136\/esmoopen-2020-000858_bb0305","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/10428190410001693588","article-title":"Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin","volume":"45","author":"Elliott","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1136\/esmoopen-2020-000858_bb0310","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6602945","article-title":"Increased risk of venous thromboembolism in patients with acute leukaemia","volume":"94","author":"Mohren","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2020-000858_bb0315","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1538-7836.2007.02383.x","article-title":"Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis","volume":"5","author":"Caruso","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1136\/esmoopen-2020-000858_bb0320","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3324\/haematol.12948","article-title":"Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study","volume":"93","author":"Hunault-Berger","year":"2008","journal-title":"Haematologica"},{"key":"10.1136\/esmoopen-2020-000858_bb0325","author":"Jarvis"},{"key":"10.1136\/esmoopen-2020-000858_bb0330","first-page":"328","article-title":"Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study","volume":"136","author":"Orvain","year":"2020","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0335","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT \u2013 a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","year":"2019","journal-title":"Haematologica"},{"key":"10.1136\/esmoopen-2020-000858_bb0340","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","article-title":"Asparaginase-associated toxicity in children with acute lymphoblastic leukemia","volume":"57","author":"Hijiya","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1136\/esmoopen-2020-000858_bb0345","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1080\/10428194.2017.1397658","article-title":"Severe pegaspargase hypersensitivity reaction rates (grade \u22653) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children\u2019s oncology group (COG) clinical trials","volume":"59","author":"Burke","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1136\/esmoopen-2020-000858_bb0350","author":"Nussbaum"},{"key":"10.1136\/esmoopen-2020-000858_bb0355","author":"Heitink-Poll\u00e9"},{"key":"10.1136\/esmoopen-2020-000858_bb0360","author":"Vrooman"},{"key":"10.1136\/esmoopen-2020-000858_bb0365","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1136\/esmoopen-2020-000858_bb0370","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2020-000858_bb0375","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1080\/10428194.2017.1386305","article-title":"Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia","volume":"59","author":"Salzer","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1136\/esmoopen-2020-000858_bb0380","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/pbc.25299","article-title":"Clinical application of asparaginase activity levels following treatment with pegaspargase","volume":"62","author":"Bleyer","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1136\/esmoopen-2020-000858_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27797","article-title":"Universal premedication and therapeutic drug monitoring for asparaginase\u2010based therapy prevents infusion\u2010associated acute adverse events and drug substitutions","volume":"66","author":"Cooper","year":"2019","journal-title":"Pediatr Blood Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920327022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920327022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2020-000858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:15Z","timestamp":1761855855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920327022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"alternative-id":["S2059702920327022"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2020-000858","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open\u2013Cancer Horizons roundtable discussion","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2020-000858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000858"}}